Literature DB >> 185361

Effect of Schistosoma mansoni infection on the hepatic drug-metabolizing capacity of mice.

Y N Cha, R Edwards.   

Abstract

Since infections with Schistosoma mansoni cause marked histopathological changes in the liver of the host, the effect of this infection on the hepatic drug-metabolizing function was investigated. Severity of Schistosomiasis was determined by worm counts, duration of infection, egg counts and liver weight increases. To overcome difficulties in homogenizing the livers of infected animals, preincubation of the squashed tissues with collagenase and hyaluronidase was used to prepare homogenates. Key component enzyme activities of the hepatic microsomal drug-metabolizing enzyme system (NADPH-cytochrome c reductase and cytochrome P-450) as well as the representative drug-metabolism activities (aminopyrine N-demethylase, aniline hydroxylase, and benzpyrene hydroxylase) were measured for the whole liver and found to be markedly reduced. However, the measurement of microsomal marker enzyme activities (cytochrome b5 and glucose-6-phosphatase) showed significant elevation. To obtain more precise information about the effect of the schistosome infection on the hepatic drug-metabolizing enzyme system, the total activities of microsomal drug-metabolizing enzymes were related to the total microsomal marker enzyme activities in the homogenate.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 185361

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  9 in total

1.  Effect of Plasmodium berghei infection on benzoic acid metabolism in mice.

Authors:  T S Emudianughe; Q D Bickle; M G Taylor; B Andrews
Journal:  Experientia       Date:  1985-11-15

2.  Effect of experimentally-induced hepatic cirrhosis on the pharmacokinetics of orally administered praziquantel in the rat.

Authors:  G O Kokwaro; G Taylor
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Jul-Sep       Impact factor: 2.441

3.  Further observations on ultrastructural changes in hepatocytes of mice infected with Schistosoma mansoni.

Authors:  L G Jones; B J Bogitsh
Journal:  Z Parasitenkd       Date:  1979-11-01

4.  Disposition of oral metronidazole in hepatic cirrhosis and in hepatosplenic schistosomiasis.

Authors:  T K Daneshmend; M Homeida; C M Kaye; A A Elamin; C J Roberts
Journal:  Gut       Date:  1982-10       Impact factor: 23.059

Review 5.  Relationship between schistosomiasis and bladder cancer.

Authors:  M H Mostafa; S A Sheweita; P J O'Connor
Journal:  Clin Microbiol Rev       Date:  1999-01       Impact factor: 26.132

6.  Drug metabolism in hepatosplenic schistosomiasis in the Sudan: a study with antipyrine.

Authors:  M Homeida; S Y Salih; R A Branch
Journal:  Gut       Date:  1978-09       Impact factor: 23.059

7.  Hepatic cytochrome P450s, phase II enzymes and nuclear receptors are downregulated in a Th2 environment during Schistosoma mansoni infection.

Authors:  Sylvie M Mimche; Beatrice A Nyagode; Matthew D Merrell; Choon-Myung Lee; Nina S Prasanphanich; Richard D Cummings; Edward T Morgan
Journal:  Drug Metab Dispos       Date:  2013-10-25       Impact factor: 3.922

8.  The pharmacokinetics of antipyrine in patients with graded severity of schistosomiasis.

Authors:  I el-Raghy; D J Back; F Osman; M A Nafeh; M L Orme
Journal:  Br J Clin Pharmacol       Date:  1985-10       Impact factor: 4.335

9.  The hepatic and duodenal activities of some drug metabolizing enzymes in chickens: influence of infection with Escherichia coli endotoxin and coccidiosis.

Authors:  B H Ali
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1997 Jul-Sep       Impact factor: 2.569

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.